In medical news:

The FDA issued a statement on the approval of Dsuvia, a sublingual (under the tongue) formulation of sufentanil that’s delivered through a disposable, pre-filled, single-dose applicator. The drug has received much public scrutiny in the midst of the opioid crisis, but the FDA argued that the benefits of a new opioid formulation outweigh the risks.

Read more here.

Leave a Comment

Your email address will not be published. Required fields are marked *